ADJUnct Semaglutide Treatment in Type 1 Diabetes

NCT05537233 · Completed

Last updated 2026-05-28

This clinical trial tests whether adding semaglutide to standard treatment helps adults with type 1 diabetes and obesity achieve better blood sugar control and weight loss compared to a placebo.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 115 people

Who can join Ages 18–65 · all sexes

Timeline Started 2023-04 · est. completion 2024-08

Where 4 sites · United States

What this study is testing ClinicalTrials.gov NCT05537233 ↗

Description as written by the study sponsor.

The purpose of this study is to assess the use of once weekly semaglutide injection in inadequately controlled obese adults with type 1 diabetes (T1D) using FDA-approved hybrid closed-loop therapies.

Treatments tested

Semaglutide Drug

Semaglutide up to 1 mg per week in addition to standard closed-loop therapy
Placebo Drug

Injection placebo up to 1 mg per week in addition to standard closed-loop therapy

Main thing measured	Proportion of Adults With T1D Achieving Composite Outcome (CGM-measured Time in Range (TIR)>70% With Time Below Range (TBR) of <4% and Reduction in Body Weight by 5%) at 26 Weeks in the Semaglutide Group Compared to Placebo Group
Sponsor	Viral N. Shah
Conditions studied	Type 1 Diabetes, Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05537233 ↗